Magazine Article | March 7, 2018

How Mesoblast Survived The Termination Of A Key Partnership, And Prospered

Source: Life Science Leader

By Michael Goodman, Contributing Writer

For most small-cap, precommercial biotechs, having a partner return a marquee program can be a nightmare scenario. Will the market view the returned assets as tainted? How will it fund the remaining clinical costs? Will it need to reduce staff, pause programs, or otherwise cut corners? In 2016 TEVA Pharmaceuticals returned rights to Mesoblast for its allogeneic stem cell treatment for advanced heart failure. TEVA, which had funded development of the program, had brought it to Phase 3, leaving Mesoblast to shoulder the cost to finish the trial as well as three other late-stage programs it was advancing internally.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: